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Editors’ NotesAiming for Application
Three papers in this issue, although describing basic research findings, have an eye toward clinical translation. In one, Zhang and
colleagues demonstrate that in vitro culture, and expansion, of mouse HSCs leads to their improved engraftment in allogeneic recip-
ients. Allogeneic BM transplantation in humans is typically hampered by the risk of graft versus host disease mediated by the transfer
of more mature blood cells, and by immune rejection of the foreign material by the host. The expansion protocol used in this case, as
Condomines and Sadelain discuss in their Preview, leads to the upregulation of the immune inhibitory molecule CD274 on both
mouse and human HSCs, and suggests that this approach may be translatable to the clinic. The findings of Hilfiker-Kleiner may
in some ways be even closer to the bedside, as Michael Schneider outlines in his In Translation article. In this study, Hoch et al.
find that heart damage caused by various cancer therapies can be overcome in mouse models by treatment with CERA, a derivative
of Erythropoietin (Epo) that is already approved for clinical use in other settings. The authors reveal amechanism for this effect, in that
replacing Epo in damaged cardiac muscle leads to upregulated CCL2/CCR2 activation, restores endothelial differentiation of
progenitors, and maintains cardiac function. The third example is admittedly considerably
further from direct medical application, but the lineage reprogramming approach taken by
Lipton and colleagues to generate functional neurons from human dermal fibroblasts may
still attract clinical interest. The induced neurons (hiNs) that are generated using a single
miRNA and two transcription factors may be particularly valuable for drug discovery and
toxicity testing, especially since hiNs can be derived from the skin of patients suffering
from specific neural diseases.Tricky Trophectoderm
Germ layer distinctions are determined early in embryonic development, and the use
of pluripotent stem cells as the starting material for many types of downstream differen-
tiated progeny makes it important to understand the pathways that regulate germ layer
identity. Previous work had suggested that BMP signals promote both mesoderm and
trophectoderm commitment in human ESCs. However, based on findings from Pedersen
and colleagues, it now appears that this signal cascade specifically directs a mesoderm
fate, rather than trophectoderm. Their results suggest that CDX2, typically considered
a trophectoderm marker, is downstream of BMP and Brachyury, and its expression in BMP-induced cells does not necessarily
indicate that a trophectoderm fate has been adopted. Another regulatory factor with a recently identified role early in the differ-
entiation of pluripotent cells is the Tet family of 5-methyl dioxygenases. Dawlaty et al. deleted Tet1 in mouse ESCs to investigate
its role in pluripotent cells, and found that despite a resulting decrease in 5hmC, the mutant ESCs were surprisingly still able to
generate live-born mice via a tetraploid complementation assay. The resulting mice are grossly normal, although somewhat
smaller at birth, and the loss of Tet1 does appear to impact differentiation of trophectoderm in vitro. It remains to be seen whether
reducing Tet activity even further by deleting other family members as well will lead to more severe phenotypes.Quirk or Quagmire?
There is a growing concern that iPSCs may bear unexpected genetic and epigenetic changes relative to nonreprogrammed cells.
Colman and colleagues add to the panel of differences observed by showing that that X-inactivation—which appears not to revert
after pluripotency is induced—is skewed toward a particular dominant active X chromosome in fibroblast cultures. This dominance
can be overcome by telomerase overexpression, but raises some caution about both
long-term cell culture and using iPSCs to model X-linked diseases. The question of
whether iPSCs can overcome the concerns that have been raised as to their suitability
for therapeutic applications, let alone basic in vitro studies, is the subject of the Perspec-
tive article from Barrilleaux and Knoepfler. The authors provide an overview of the many
reported differences between and among iPSC populations, and make several sugges-
tions as to how the field might be best served to focus ongoing research efforts with
clinical goals in mind. Concerns about the genomic integrity of stem cells are not limited
to the iPSC landscape. In a Synthesis article, Benvenisty and colleagues use their estab-
lished method of surveying expression array data to uncover genetic abnormalities in
a large number of published data sets. The resulting analysis revealed that other stem
cell populations, notably NSCs and MSCs, have a tendency to accumulate chromosomal
aberrations at a similar frequency as that observed in pluripotent cells, and this pattern
does not require long culture periods to surface. The authors also detected similar abnor-
malities in certain human tumors. Their findings raise questions about whether culturing of
many types of stem cells, and not just pluripotent cells, is prone to genetic instability.Cell Stem Cell 9, August 5, 2011 ª2011 Elsevier Inc. xi
